About the Center for Technology Licensing (CTL)
CTL is Cornell University's technology transfer office. We manage Cornell technologies from Cornell's Ithaca campus, Weill Cornell Medical Colleges, Cornell Tech, and Cornell AgriTech in Geneva.
Cornell Products
The following are products that are currently on the market based on licensed Cornell technology.
Available Cornell Technologies
- Combination Cancer Therapy Involving the Chronic Use of Low Doses of ATR Signaling Inhibitors
- Raspberry 'Crimson Treasure'
- Multiplex Diagnostic Test for Equine Herpes Virus Type 1
- Treatment of Cardiac Disorder with Nicotinamide Riboside
- Use of a single massively multiplex digital PCR assay for minimal residual disease (MRD) assessment in acute myeloid leukemia (AML) patients
- Novel Annexin A2 Antibodies as Therapeutics for Diabetic Retinopathy and Proliferative Vitreoretinopathy
|
Blood-Brain Barrier, Protecting the Brain |
After Margaret Bynoe and her lab discovered that an FDA-approved drug, Lexiscan, used in cardiac imaging, could open the blood-brain barrier, the lab went to work, exploring how it could be used as a therapeutic for brain diseases.
|
From Lab to Invaluable Energy Innovations |
Lynden Archer is searching for ways to give fossil fuels a different life. His lab has already discovered some invaluable new processes and products.
|
Mindless Computing Technology for Health |
A wrist device lowers heart rate; a bedside device monitors sleep quality; a dinner plate controls food quantity. Tanzeem Choudhury makes it happen.
|
Mobile Gene Content |
Ilana L. Brito and her team are developing a suite of computational tools for examining the mobile gene content in multiple datasets — to identify those genes that may shape the response of microbial communities to stress.
|
Tackling Cyberfinance Security |
Emin Gün Sirer's research group developed and tested Falcon — which they call fast and fierce — for processing Bitcoin blockchains, digital transaction ledgers.
|
The Lifestyle of Bacteria |
When bacteria live in a community known as biofilm, antibiotics can't enter to fight infection. Holger Sondermann wants to disperse that community.
